Arrowhead Pharmaceuticals, Inc. (ARWR)
Largest Insider Buys in Sector
ARWR Stock Price History Chart
ARWR Stock Performance
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Activity of Arrowhead Pharmaceuticals, Inc.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $7.57M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $94,564 and sold $20.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $165,980.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
List of Insider Buy and Sell Transactions, Arrowhead Pharmaceuticals, Inc.
| 2025-01-07 | Sale | COO and General Counsel | 8,000 0.0065% | $19.69 | $157,520 | -3.86% | ||
| 2025-01-07 | Sale | Chief Financial Officer | 18,000 0.0146% | $19.69 | $354,500 | -3.86% | ||
| 2025-01-06 | Sale | COO and General Counsel | 29,184 0.0236% | $19.82 | $578,539 | -2.97% | ||
| 2025-01-06 | Sale | Chief Financial Officer | 27,167 0.022% | $19.83 | $538,595 | -2.97% | ||
| 2025-01-06 | Sale | Chief Discovery/Trans Medicine | 32,729 0.0265% | $19.82 | $648,824 | -2.97% | ||
| 2025-01-02 | Sale | Chief Executive Officer | 11,520 0.009% | $19.05 | $219,456 | -2.21% | ||
| 2024-12-27 | Sale | director | 2,850 0.0024% | $20.00 | $57,000 | -0.16% | ||
| 2024-12-23 | Sale | Chief Executive Officer | 12,563 0.0099% | $19.59 | $246,109 | -4.00% | ||
| 2024-12-18 | Sale | Chief Executive Officer | 26,712 0.0226% | $21.24 | $567,486 | 0.00% | ||
| 2024-12-17 | Sale | director | 547 0.0004% | $22.04 | $12,056 | -12.66% | ||
| 2024-12-17 | Sale | director | 3,747 0.003% | $22.04 | $82,584 | -12.66% | ||
| 2024-12-16 | Sale | director | 5,000 0.004% | $21.90 | $109,500 | -12.94% | ||
| 2024-12-16 | Sale | director | 3,748 0.003% | $21.90 | $82,081 | -12.94% | ||
| 2024-12-16 | Sale | director | 8,994 0.0071% | $21.91 | $197,059 | -12.94% | ||
| 2024-07-02 | Sale | Chief Commercial Officer | 9,394 0.0073% | $25.28 | $237,480 | 0.00% | ||
| 2024-05-02 | Sale | director | 1,799 0.0014% | $23.31 | $41,935 | -5.12% | ||
| 2024-04-01 | Sale | Chief Discovery/Trans Medicine | 6,000 0.0048% | $28.03 | $168,180 | -18.06% | ||
| 2024-03-20 | director | 1,000 0.0008% | $27.50 | $27,500 | -17.19% | |||
| 2024-03-19 | director | 1,000 0.0008% | $28.00 | $28,000 | -15.83% | |||
| 2024-03-18 | director | 1,000 0.0008% | $27.49 | $27,490 | -16.86% |
Insider Historical Profitability
| Anzalone Christopher Richard | Chief Executive Officer | 3764252 3.0251% | $18.98 | 4 | 38 | <0.0001% |
| O'Brien Patrick | COO and General Counsel | 527201 0.4237% | $18.98 | 0 | 13 | |
| Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.366% | $18.98 | 1 | 29 | <0.0001% |
| Hamilton James C | Chief Discovery/Trans Medicine | 272122 0.2187% | $18.98 | 0 | 13 | |
| Oliver Tracie | Chief Commercial Officer | 127107 0.1021% | $18.98 | 0 | 3 | |
| GIVEN DOUGLAS B | director | 124167 0.0998% | $18.98 | 1 | 21 | <0.0001% |
| Waddill William D. | director | 40378 0.0324% | $18.98 | 0 | 9 | |
| OLUKOTUN ADEOYE Y | director | 36740 0.0295% | $18.98 | 0 | 4 | |
| Lu Hongbo | director | 33680 0.0271% | $18.98 | 3 | 0 | |
| Vakiener Victoria | director | 21211 0.017% | $18.98 | 0 | 4 | |
| GIVEN BRUCE D | Chief Operating Officer | 850730 0.6837% | $18.98 | 0 | 19 | |
| Li Zhen | Snr. VP, Chem and Non-Clin Dev | 201700 0.1621% | $18.98 | 0 | 1 | |
| San Martin Javier | Chief Medical Officer | 198497 0.1595% | $18.98 | 0 | 5 | |
| KNOTT DAVID M | 10 percent owner | 166778 0.134% | $18.98 | 1 | 3 | <0.0001% |
| Leone Peter Brian | VP, Strategic Bus. Initiatives | 130000 0.1045% | $18.98 | 0 | 1 | |
| Hassard James | Chief Commercial Officer | 105750 0.085% | $18.98 | 0 | 2 | |
| PERRY MICHAEL S | director | 85500 0.0687% | $18.98 | 0 | 5 | |
| Ferrari Mauro | director | 60778 0.0488% | $18.98 | 2 | 4 | +71% |
| FRYKMAN EDWARD W | director | 23852 0.0192% | $18.98 | 0 | 1 | |
| McKenney Charles | director | 17220 0.0138% | $18.98 | 1 | 16 | |
| De Backer Marianne | director | 17000 0.0137% | $18.98 | 9 | 2 | +50.28% |
| Kingsley Joseph Theodore III | Interim President & CFO | 12000 0.0096% | $18.98 | 2 | 0 | +27.69% |
| Ching Marshall Robert | 10 percent owner | 0 0% | $18.98 | 0 | 6 | |
| Lewis David L. | Chief Scientific Officer | 0 0% | $18.98 | 0 | 3 | |
| Bradshaw Curt | Chief Scientific Officer | 0 0% | $18.98 | 0 | 2 |
Institutional Investor Ownership
| BlackRock | $438.91M | 12.36 | 15.35M | +15.36% | +$58.43M | 0.01 | |
| The Vanguard Group | $354.76M | 9.99 | 12.4M | +16.23% | +$49.53M | 0.01 | |
| Avoro Capital Advisors Llc | $244.69M | 6.89 | 8.56M | +657.13% | +$212.37M | 2.93 | |
| State Street | $187.64M | 5.28 | 6.56M | -3.87% | -$7.56M | 0.01 | |
| Fidelity Investments | $182.89M | 5.15 | 6.39M | +89.68% | +$86.47M | 0.01 | |
| Slate Path Capital LP | $118.38M | 3.33 | 4.14M | +211.44% | +$80.37M | 2.34 | |
| Artal Group S A | $86.85M | 2.45 | 3.04M | +195.32% | +$57.44M | 0.38 | |
| Geode Capital Management | $78.79M | 2.22 | 2.75M | +18.38% | +$12.24M | 0.01 | |
| JPMorgan Chase | $75.45M | 2.12 | 2.64M | -4.11% | -$3.23M | 0.01 | |
| T Rowe Price Investment Management Inc | $50.3M | 1.42 | 1.76M | New | +$50.3M | 0.03 | |
| Credit Suisse | $46.52M | 1.31 | 1.63M | -6.81% | -$3.4M | 0.04 | |
| Northern Trust | $37.2M | 1.05 | 1.3M | +5.78% | +$2.03M | 0.01 | |
| Rokos Capital Management | $35.15M | 0.99 | 1.23M | 0% | +$0 | 0.92 | |
| Morgan Stanley | $32.49M | 0.92 | 1.14M | +26.28% | +$6.76M | <0.01 | |
| BNY Mellon | $30.17M | 0.85 | 1.05M | +10.13% | +$2.78M | 0.01 | |
| Goldman Sachs | $30.02M | 0.85 | 1.05M | -1.17% | -$355,440.79 | 0.01 | |
| Ameriprise Financial | $28.52M | 0.8 | 997,297 | +7.4% | +$1.96M | 0.01 | |
| Charles Schwab | $28.14M | 0.79 | 983,755 | +16.29% | +$3.94M | 0.01 | |
| Ubs Asset Management Americas Inc | $26.71M | 0.75 | 933,900 | -1.83% | -$497,468.40 | 0.01 | |
| Spyglass Capital Management LLC | $25.98M | 0.73 | 908,474 | 0% | +$0 | 19.47 | |
| Western Financial Corp Ca | $23.46M | 0.66 | 820,239 | 0% | +$0 | 14.71 | |
| Citadel Advisors LLC | $21.22M | 0.6 | 741,897 | +1,165.24% | +$19.54M | 0.01 | |
| OrbiMed | $21.15M | 0.6 | 739,651 | +131.39% | +$12.01M | 0.16 | |
| Woodline Partners LP | $15.89M | 0.45 | 555,628 | -40.07% | -$10.63M | 0.14 | |
| Capital International Investors | $13.7M | 0.39 | 479,106 | -62.5% | -$22.84M | <0.01 | |
| Bank of America | $13.18M | 0.37 | 460,770 | -21.32% | -$3.57M | <0.01 | |
| UBS | $12.9M | 0.36 | 450,921 | -11.34% | -$1.65M | <0.01 | |
| Schonfeld Group | $11.89M | 0.34 | 415,783 | -9.67% | -$1.27M | 0.07 | |
| RhumbLine Advisers | $10.64M | 0.3 | 372,105 | +15.43% | +$1.42M | 0.01 | |
| Susquehanna International Group | $10.28M | 0.29 | 359,470 | +329% | +$7.88M | 0.01 | |
| Retirement Systems of Alabama | $9.98M | 0.28 | 348,784 | +6.51% | +$610,066.58 | 0.04 | |
| Assenagon Asset Management S.A. | $9.85M | 0.28 | 344,467 | +796.86% | +$8.75M | 0.02 | |
| Mirae Asset Global Investments Co Ltd | $8M | 0.26 | 327,782 | +67.25% | +$3.22M | 0.01 | |
| Nuveen | $9.38M | 0.26 | 328,033 | -4.78% | -$471,070.61 | <0.01 | |
| Millennium Management LLC | $9.35M | 0.26 | 326,971 | New | +$9.35M | 0.01 | |
| Eventide Asset Management | $8.96M | 0.25 | 313,289 | 0% | +$0 | 0.15 | |
| Citigroup | $8.04M | 0.23 | 280,984 | +50.3% | +$2.69M | 0.01 | |
| Privium Fund Management | $7.83M | 0.22 | 273,936 | 0% | +$0 | 2.33 | |
| Rafferty Asset Management Llc | $7.84M | 0.22 | 274,159 | -24.91% | -$2.6M | 0.02 | |
| Legal & General | $7.84M | 0.22 | 274,050 | -0.58% | -$45,388.19 | <0.01 | |
| Invesco | $7.27M | 0.21 | 254,240 | -88.98% | -$58.69M | <0.01 | |
| Octagon Capital Advisors LP | $7.15M | 0.2 | 250,000 | New | +$7.15M | 0.04 | |
| Johnson & Johnson | $7.08M | 0.2 | 247,598 | 0% | +$0 | 0.17 | |
| AllianceBernstein | $6.97M | 0.2 | 243,853 | +8.03% | +$518,460.82 | <0.01 | |
| Swiss National Bank | $6.96M | 0.2 | 243,300 | +21.23% | +$1.22M | 0.01 | |
| Russell Investments Group Ltd | $6.94M | 0.2 | 242,636 | -2.09% | -$148,176.97 | 0.01 | |
| Deutsche Bank | $6.65M | 0.19 | 232,451 | -4.02% | -$278,278.02 | <0.01 | |
| Candriam S C A | $6.52M | 0.18 | 228,054 | +23.24% | +$1.23M | 0.04 | |
| WCM Investment Management | $6.45M | 0.18 | 225,583 | +30.5% | +$1.51M | 0.02 | |
| Barclays | $6.38M | 0.18 | 223,148 | -38.35% | -$3.97M | <0.01 |